Data as of 2026-09-16.
Lymphomas divide first into Hodgkin and non-Hodgkin lymphoma (NHL). NHL is itself an umbrella for many B- and T-cell entities; the highest-volume B-cell subtypes — DLBCL, follicular, mantle cell, and CLL/SLL — each carry their own pipeline of targeted agents, bispecific antibodies, and cell therapies. Tracking lymphoma well means watching both the broad NHL category and the individual subtype races, since a single new bispecific or CAR-T program often spans several of them.
Non-Hodgkin lymphoma is an umbrella covering the B-cell subtypes listed below, so the rows overlap and do not sum to the total above. CLL/SLL is biologically a small-cell B-cell lymphoma and is included here as well as on the blood-cancer hub.
Major categories
| Subtype | Active | Recruiting | Phase 3 |
|---|---|---|---|
| Non-Hodgkin Lymphoma | 1286 | 721 | 94 |
| Hodgkin Lymphoma | 227 | 122 | 12 |
B-cell non-Hodgkin subtypes
| Subtype | Active | Recruiting | Phase 3 |
|---|---|---|---|
| Chronic Lymphocytic Leukemia / SLL | 390 | 191 | 44 |
| Diffuse Large B-Cell Lymphoma (DLBCL) | 563 | 308 | 50 |
| Follicular Lymphoma | 272 | 142 | 30 |
| Mantle Cell Lymphoma | 212 | 109 | 11 |
Track every new lymphoma trial automatically
ClinicalTrials.gov updates daily. Our pipeline monitors it for you and delivers a clean digest every morning.
Get the free digest, no credit cardLargest industry-sponsored lymphoma trial portfolios by active study count:
| Industry sponsor | Active trials |
|---|---|
| AstraZeneca | 26 |
| Roche / Genentech | 21 |
| Merck (MSD) | 17 |
| Bristol-Myers Squibb | 16 |
| Genmab | 14 |
Our pipeline pulls from ClinicalTrials.gov every day. For a lymphoma watchlist or saved search, your digest covers:
- New study registrations and status changes (for example opened to recruiting, completed)
- Protocol changes: enrollment, endpoints, phase, and completion-date movements
- New sponsor entrants into a subtype
- Phase filters (Phase 1 for novel mechanisms, Phase 3 for registration programs)
- Sponsor-type filters (large pharma vs. emerging biotech vs. academic)
Ready to automate your lymphoma trial monitoring?
Free plan, no credit card required. Set up your profile in 2 minutes.
Start freeFrequently asked questions
DataLookout checks ClinicalTrials.gov every day and records what changed on each trial: status, enrollment, phase, primary endpoint, completion dates, sites, sponsor, and the stated reason a trial stopped. Add a sponsor or a disease to your watchlist, or save any search, and the changes arrive in a daily or weekly email digest.
Free, $0 forever: 1 sponsor + 1 disease watchlist, 1 saved search in your email digest, track up to 5 individual trials, daily change detection, Trials at Risk (top trial). No credit card.
Starter, $49/month: 3 sponsor + 3 disease watchlists, 3 saved searches in your email digest, track up to 25 individual trials, full Trials at Risk list and landscape reports.
Pro, $149/month: unlimited sponsor and disease watchlists, unlimited saved searches, track unlimited individual trials, CSV export, priority email support.
Data as of 2026-09-16, from ClinicalTrials.gov. View the full pipeline on the dashboard.